The Globe and Mail reports in its Thursday, May 1, edition that Scotia Capital analyst Kevin Krishnaratne started coverage on Healwell AI with a "sector outperform" ranking and a $2.50 share target. The Globe's David Leeder writes that analysts on average target the shares at $3.55. Mr. Krishnaratne says in a note: "We believe Healwell AI is in the early stages of its pursuit to drive better patient outcomes by leveraging its AI and natural language processing (NLP) expertise to detect early signals of rare and complex diseases within the noise of unstructured healthcare data across electronic medical record (EMR) systems, health information exchanges (HIEs), clinical notes, medical images, among many other sources. Healthcare software provides defensive, recurring, and profitable global business and serves as a key distribution channel for current and future AI products." The Globe reported on March 13 that Raymond James analyst Michael Freeman had commenced coverage on Healwell AI with an "outperform" recommendation. The shares could then be had for $1.47. The Globe reported on April 25 that Canaccord's Doug Taylor had started coverage on Healwell AI with a "speculative buy" ranking. It was then worth $1.47.